Moneycontrol PRO
HomeNewsBusinessManipal-TPG eyes majority stake in Medanta, values co at Rs 6,000 crore: Report

Manipal-TPG eyes majority stake in Medanta, values co at Rs 6,000 crore: Report

Manipal-TPG is likely to offer a valuation of Rs 6,000 crore for Medanta

October 24, 2018 / 11:20 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    TPG Capital and Manipal Health Enterprises are in talks to jointly acquire majority stake in hospital operator Medanta from heart surgeon Naresh Trehan and other investors, Mint reported.

    Trehan, his family, and Medanta co-founder Sunil Sachdeva own around 55 percent stake in the Gurugram-based hospital. US-based private equity fund Carlyle Group owns 27 percent in Global Health, which owns, manages and operates Medanta, while Singapore’s Temasek Holdings holds 18 percent stake.

    "While the discussions are still on and it is yet to submit a bid, Manipal-TPG is likely to offer a valuation of Rs 6,000 crore for Medanta," a source told the paper.

    Moneycontrol could not independently verify the report.

    Earlier, Malaysia’s IHH Healthcare had submitted a bid for Medanta, valuing the firm at around Rs 5,700 crore. IIH, however, withdrew its non-binding bid following its acquisition of the hospital business of crisis-ridden Fortis Healthcare in July, outbidding TPG-Manipal.

    Read: IHH wins Fortis bid — Meet CEO Tan See Leng, a bus timekeeper's son key to Malaysian co's rise to the top

    Medanta's acquisition would help TPG Capital further expand its healthcare systems in India as the US-based company has been sharpening its focus on healthcare investments in India since 2016, the report said.

    "TPG has been actively looking to build Asia Healthcare Holdings -- its healthcare platform. Medanta’s acquisition will help the private equity firm diversify its healthcare investments," another source told the paper.

    As of now, TPG Capital's healthcare portfolio in the country includes Cancer Treatment Services International; Bengaluru-based Rhea Healthcare, the operator of hospitals for women and children under Motherhood brand; and Sai Life Sciences, a drug discovery and manufacturing firm.

    Medanta has been under pressure because of price controls imposed by the National Pharmaceutical Pricing Authority (NPPA), the drug pricing regulator. The latter capped the prices of ortho knee implants, citing public interest, in August last year. Earlier this year, NPPA further cut the ceiling prices of the most commonly used drug-eluting stent (DES) by 5.8 percent.

    These controls brought down DES prices to about Rs 30,000 from around Rs 2 lakh, hurting revenues of hospitals in India.

    According to the report, Medanta also reported a decline in its revenue after several of its top doctors quit to join rivals such as Fortis and Max Healthcare.

    Medanta operates hospitals and clinics across cities including Gurugram, Lucknow, Indore, Ranchi, and Sri Ganganagar.

    Moneycontrol News
    first published: Oct 24, 2018 11:20 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347